{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:26:00Z","timestamp":1789388760610,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Synthetic cathinones that are primarily smoked\u2014such as pyrovalerone-type compounds, including MDPV, MDPHP, \u03b1-PHP, and \u03b1-PHiP, often referred to as \u201cMonkey Dust\u201d\u2014have raised growing concern in clinical and harm reduction contexts due to their association with severe adverse psychological and behavioral effects. To date, detailed empirical user-level data on patterns of use and related aspects are absent. To address this gap, the present study aims to integrate first-hand perspectives and key characteristics of individuals using smokable synthetic cathinones to examine patterns of use and experiences associated with these substances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>As part of a large cross-sectional online survey on synthetic cathinone use in general, this study investigated the use of smokable synthetic cathinones in Germany (March\u2013May 2025). A sample of 107 participants who reported use within the past 12\u00a0months was analyzed in detail. Quantitative measures\u2014combined with content analysis of open-text responses\u2014captured sociodemographics, patterns, settings, and motives of use, mental and physical health, adverse effects, reduction efforts, and support needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The majority of individuals who used smokable synthetic cathinones matched typical chemsex profiles (male, homosexual, urban, highly educated), yet non-chemsex use populations were also identified. One quarter reported using at least once a week and had high rates of problematic or dependent use indicators. One third reported a current mental disorder and symptoms of depression and anxiety were common. Frequently reported adverse effects included psychotic symptoms, anxiety, and panic attacks\u2014consistent with the clinical profiles (e.g., sympathomimetic characteristics) typical of smokable synthetic cathinones\u2014and were particularly prevalent among those reporting frequent use. Around one third reported applying safer use strategies, and nearly half had initiated reduction or cessation efforts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the first systematic user-centered insights into the use of smokable synthetic cathinones, revealing heterogeneous populations with varying use patterns and risks. The findings highlight the need for targeted prevention and support strategies that address both chemsex-related and other emerging use profiles and settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>The study was prospectively preregistered with the German Clinical Trials Register (DRKS; drks.de\/search\/en\/trial\/DRKS00035946) in February 2025.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-026-01428-8","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:33:18Z","timestamp":1771993998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From dust till dawn: patterns, motives, and risks of using smokable synthetic cathinones"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-6205","authenticated-orcid":false,"given":"Antonia","family":"Bendau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paale","family":"Bournot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1389-4870","authenticated-orcid":false,"given":"Felix","family":"Betzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Clay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Desaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-1996","authenticated-orcid":false,"given":"Twyla","family":"Michnevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"1428_CR1","unstructured":"Clay C, Vellguth B. Entwicklung von Informationen zur Schadensminimierung f\u00fcr \u201eMonkey Dust\u201c: Poster Presentation at Chemkon 2025 Berlin; 2025."},{"key":"1428_CR2","unstructured":"Koenigs EV. Zerst\u00f6rerische Droge \u201eFlex\u201c breitet sich in Niedersachsen aus. NDR. 2023. https:\/\/www.ndr.de\/nachrichten\/niedersachsen\/Extrem-gefaehrliche-Droge-Flex-breitet-sich-in-Niedersachsen-aus,flex106.html. Accessed 10 Aug 2025."},{"key":"1428_CR3","unstructured":"Advisory Council on the Misuse of Drugs (ACMD). Synthetic cathinones: an updated harms assessment. 2025. https:\/\/clok.uclan.ac.uk\/id\/eprint\/54373\/1\/Synthetic_Cathinones_final_4_-_3_February.pdf. Accessed 10 Aug 2025."},{"key":"1428_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2024.112297","volume":"365","author":"P Kriikku","year":"2024","unstructured":"Kriikku P, Ojanper\u00e4 I. Findings of synthetic cathinones in post-mortem toxicology. Forensic Sci Int. 2024;365:112297. https:\/\/doi.org\/10.1016\/j.forsciint.2024.112297.","journal-title":"Forensic Sci Int"},{"key":"1428_CR5","unstructured":"Google Trends. Relative search interest for \u201cMonkey Dust\u201d in Germany over the last ten years. 2026. https:\/\/trends.google.de\/explore?q=monkey%20dust0026date=2016-01-01%202025-12-310026geo=DE. Accessed 18 Jan 2026."},{"key":"1428_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jemermed.2013.11.104","volume":"46","author":"ML Banks","year":"2014","unstructured":"Banks ML, Worst TJ, Rusyniak DE, Sprague JE. Synthetic cathinones (\u201cbath salts\u201d). J Emerg Med. 2014;46:632\u201342.","journal-title":"J Emerg Med"},{"key":"1428_CR7","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol. EU Drug Market: New psychoactive substances\u2014Distribution and supply in Europe: Synthetic cathinones; 2024."},{"key":"1428_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.neuropharm.2017.10.007","volume":"134","author":"L Karila","year":"2018","unstructured":"Karila L, Lafaye G, Scocard A, Cottencin O, Benyamina A. MDPV and \u03b1-PVP use in humans: the twisted sisters. Neuropharmacology. 2018;134:65\u201372.","journal-title":"Neuropharmacology"},{"key":"1428_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/life14040429","volume":"14","author":"P Dinis","year":"2024","unstructured":"Dinis P, Franco J, Margalho C. \u03b1-Pyrrolidinohexanophenone (\u03b1-PHP) and \u03b1-Pyrrolidinoisohexanophenone (\u03b1-PiHP): a review. Life. 2024;14:429.","journal-title":"Life"},{"key":"1428_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.brainresbull.2016.04.011","volume":"126","author":"RA Glennon","year":"2016","unstructured":"Glennon RA, Young R. Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and \u03b1-pyrrolidinovalerophenone (\u03b1-PVP). Brain Res Bull. 2016;126:111\u201326. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.04.011.","journal-title":"Brain Res Bull"},{"key":"1428_CR11","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1093\/jat\/bkac092","volume":"46","author":"M Deville","year":"2023","unstructured":"Deville M, Fedorowicz R, Grandjean F, Simon M, Charlier C. Synthetic cathinones in Belgium: two case reports with different outcomes observed in the emergency room. J Anal Toxicol. 2023;46:e291\u20135. https:\/\/doi.org\/10.1093\/jat\/bkac092.","journal-title":"J Anal Toxicol"},{"key":"1428_CR12","unstructured":"Sidekicks Berlin. Monkey Dust. 2024. https:\/\/sidekicks.berlin\/en\/monkeydust\/. Accessed 22 Aug 2025."},{"key":"1428_CR13","unstructured":"European Union Drug Agency (EUDA). Synthetic stimulants - the current situation in Europe (European Drug Report 2025). 2025. https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/synthetic-stimulants_en. Accessed 6 Nov 2025."},{"key":"1428_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.toxlet.2011.10.002","volume":"208","author":"M Coppola","year":"2012","unstructured":"Coppola M, Mondola R. 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett. 2012;208:12\u20135. https:\/\/doi.org\/10.1016\/j.toxlet.2011.10.002.","journal-title":"Toxicol Lett"},{"key":"1428_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11419-022-00639-5","volume":"41","author":"P Kuropka","year":"2023","unstructured":"Kuropka P, Zawadzki M, Szpot P. A review of synthetic cathinones emerging in recent years (2019\u20132022). Forensic Toxicol. 2023;41:25\u201346. https:\/\/doi.org\/10.1007\/s11419-022-00639-5.","journal-title":"Forensic Toxicol"},{"key":"1428_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/1178221817716391","volume":"11","author":"MJ Barratt","year":"2017","unstructured":"Barratt MJ, Ferris JA, Zahnow R, Palamar JJ, Maier LJ, Winstock AR. Moving on from representativeness: testing the utility of the Global Drug Survey. Subst Abuse. 2017;11:1178221817716391. https:\/\/doi.org\/10.1177\/1178221817716391.","journal-title":"Subst Abuse"},{"key":"1428_CR17","unstructured":"World Health Organization (WHO). Critical review report: Critical review report: \u03b1-Pyrrolidinoisohexanophenone (\u03b1-PiHP): Expert Committee on Drug Dependence Forty-fifth Meeting; 2022."},{"key":"1428_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2012.11.020","volume":"698","author":"MH Baumann","year":"2013","unstructured":"Baumann MH, Partilla JS, Lehner KR. Psychoactive \u201cbath salts\u201d: not so soothing. Eur J Pharmacol. 2013;698:1\u20135. https:\/\/doi.org\/10.1016\/j.ejphar.2012.11.020.","journal-title":"Eur J Pharmacol"},{"key":"1428_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13168","volume":"27","author":"MS Abbott","year":"2022","unstructured":"Abbott MS, Seaman RW, Doyle MR, Maguire DR, Rice KC, Collins GT. Interactions between impulsivity and MDPV self-administration in rats. Addict Biol. 2022;27:e13168. https:\/\/doi.org\/10.1111\/adb.13168.","journal-title":"Addict Biol"},{"key":"1428_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.annemergmed.2012.01.005","volume":"60","author":"HA Borek","year":"2012","unstructured":"Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of \u201cbath salts\u201d containing 3, 4-methylenedioxypyrovalerone. Ann Emerg Med. 2012;60:103\u20135.","journal-title":"Ann Emerg Med"},{"key":"1428_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076230","author":"G Daziani","year":"2023","unstructured":"Daziani G, Lo Faro AF, Montana V, Goteri G, Pesaresi M, Bambagiotti G, et al. Synthetic cathinones and neurotoxicity risks: a systematic review. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24076230.","journal-title":"Int J Mol Sci"},{"key":"1428_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/15563650.2011.590812","volume":"49","author":"HA Spiller","year":"2011","unstructured":"Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of \u201cbath salts\u201d and \u201clegal highs\u201d (synthetic cathinones) in the United States. Clin Toxicol Phila. 2011;49:499\u2013505. https:\/\/doi.org\/10.3109\/15563650.2011.590812.","journal-title":"Clin Toxicol Phila"},{"key":"1428_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.neuro.2016.05.015","volume":"55","author":"JA Marusich","year":"2016","unstructured":"Marusich JA, Lefever TW, Blough BE, Thomas BF, Wiley JL. Pharmacological effects of methamphetamine and alpha-PVP vapor and injection. Neurotoxicology. 2016;55:83\u201391.","journal-title":"Neurotoxicology"},{"key":"1428_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3460849","volume":"2016","author":"C Crespi","year":"2016","unstructured":"Crespi C. Flakka-induced prolonged psychosis. Case Rep Psychiatry. 2016;2016:3460849. https:\/\/doi.org\/10.1155\/2016\/3460849.","journal-title":"Case Rep Psychiatry"},{"key":"1428_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.115974","volume":"241","author":"D Arillotta","year":"2024","unstructured":"Arillotta D, Totti A, Dimitrova A, Croce EB, Di Milia MG, Gambassi F, et al. Clinical manifestations and analytical reports for MDPHP acute intoxication cases. J Pharm Biomed Anal. 2024;241:115974. https:\/\/doi.org\/10.1016\/j.jpba.2024.115974.","journal-title":"J Pharm Biomed Anal"},{"key":"1428_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s12640-016-9640-6","volume":"30","author":"J Wojcieszak","year":"2016","unstructured":"Wojcieszak J, Andrzejczak D, Woldan-Tambor A, Zawilska JB. Cytotoxic activity of pyrovalerone derivatives, an emerging group of psychostimulant designer cathinones. Neurotox Res. 2016;30:239\u201350. https:\/\/doi.org\/10.1007\/s12640-016-9640-6.","journal-title":"Neurotox Res"},{"key":"1428_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00115-021-01116-x","volume":"93","author":"M Gertzen","year":"2022","unstructured":"Gertzen M, Strasburger M, Geiger J, Rosenberger C, Gernun S, Schwarz J, et al. Chemsex: a new challenge in addiction medicine and infectious diseases. [Chemsex: a new challenge in addiction medicine and infectious diseases]. Nervenarzt. 2022;93:263\u201378. https:\/\/doi.org\/10.1007\/s00115-021-01116-x.","journal-title":"Nervenarzt"},{"key":"1428_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/09687637.2020.1799944","volume":"28","author":"AM Atkinson","year":"2021","unstructured":"Atkinson AM, Sumnall H. \u2018Zombies\u2019, \u2018cannibals\u2019, and \u2018super humans\u2019\u202f: a quantitative and qualitative analysis of UK news media reporting of the cathinone psychostimulants labelled \u2018monkey dust.\u2019 Drugs Educ Prev Policy. 2021;28:299\u2013315. https:\/\/doi.org\/10.1080\/09687637.2020.1799944.","journal-title":"Drugs Educ Prev Policy"},{"key":"1428_CR29","unstructured":"Leiner DJ. SoSci survey (version 3.1. 06)[computer software]. M\u00fcnchen: SoSci Survey GmbH. 2019."},{"key":"1428_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01152-9","volume":"22","author":"A Bendau","year":"2025","unstructured":"Bendau A, Roediger L, Piest A, Schmolke R, Ahrend K, Petzold MB, et al. Mind the G(ap): bridging prevention needs and approaches for GHB\/GBL users and their social environment. Harm Reduct J. 2025;22:5. https:\/\/doi.org\/10.1186\/s12954-025-01152-9.","journal-title":"Harm Reduct J"},{"key":"1428_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/16066359.2025.2605963","author":"A Bendau","year":"2025","unstructured":"Bendau A, Roediger L, Petzold MB, Schmolke R, Michnevich T, Betzler F. Dancing on the edge? The motivational drivers of Gamma-Hydroxybutyrate\/Gamma-Butyrolactone use\u2014a longitudinal mixed-methods study. Addict Res Theory. 2025. https:\/\/doi.org\/10.1080\/16066359.2025.2605963.","journal-title":"Addict Res Theory"},{"key":"1428_CR32","first-page":"613","volume":"50","author":"K Kroenke","year":"2009","unstructured":"Kroenke K, Spitzer RL, Williams JBW, L\u00f6we B. An ultra-brief screening scale for anxiety and depression: the PHQ\u20134. Psychosomatics. 2009;50:613\u201321.","journal-title":"Psychosomatics"},{"key":"1428_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jad.2009.06.019","volume":"122","author":"B L\u00f6we","year":"2010","unstructured":"L\u00f6we B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122:86\u201395.","journal-title":"J Affect Disord"},{"key":"1428_CR34","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2012.121","author":"G Balestroni","year":"2012","unstructured":"Balestroni G, Bertolotti G. EuroQol-5D (EQ-5D): an instrument for measuring quality of life. Monaldi Arch Chest Dis. 2012. https:\/\/doi.org\/10.4081\/monaldi.2012.121.","journal-title":"Monaldi Arch Chest Dis"},{"key":"1428_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/her\/16.4.457","volume":"16","author":"A Boys","year":"2001","unstructured":"Boys A, Marsden J, Strang J. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res. 2001;16:457\u201369.","journal-title":"Health Educ Res"},{"key":"1428_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000501310","volume":"25","author":"F Betzler","year":"2019","unstructured":"Betzler F, Ernst F, Helbig J, Viohl L, Roediger L, Meister S, et al. Substance use and prevention programs in Berlin\u2019s party scene: results of the SuPrA-study. Eur Addict Res. 2019;25:283\u201392.","journal-title":"Eur Addict Res"},{"key":"1428_CR37","first-page":"135","volume":"94","author":"RL Brown","year":"1995","unstructured":"Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J. 1995;94:135\u201340.","journal-title":"Wis Med J"},{"key":"1428_CR38","unstructured":"Bundeszentrale f\u00fcr gesundheitliche Aufkl\u00e4rung (BzgA). \u00c4rztliches Manual zur Pr\u00e4vention und Behandlung von riskantem, sch\u00e4dlichem und abh\u00e4ngigem Konsum.; 2021."},{"key":"1428_CR39","unstructured":"IBM Corp. IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp.; 2022."},{"key":"1428_CR40","volume-title":"Psychology of substance abuse: psychotherapy, clinical management and social intervention","year":"2021","unstructured":"Andrade ALM, de Micheli D, Da Silva EA, Lopes FM, de Oliveira Pinheiro B, Reichert RA, editors. Psychology of substance abuse: psychotherapy, clinical management and social intervention. Berlin: Springer; 2021."},{"key":"1428_CR41","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1017\/S0033291722000502","volume":"53","author":"T Robinson","year":"2023","unstructured":"Robinson T, Ali MU, Easterbrook B, Hall W, Jutras-Aswad D, Fischer B. Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. Psychol Med. 2023;53:3858\u201368. https:\/\/doi.org\/10.1017\/S0033291722000502.","journal-title":"Psychol Med"},{"key":"1428_CR42","unstructured":"Champely S. WR: Basic Functions for Power Analysis. R Package Version 1.3-0; 2025. https:\/\/CRAN.R-project.org\/package=pwr."},{"key":"1428_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/a-2283-5049","volume":"25","author":"D Deimel","year":"2024","unstructured":"Deimel D, Bohn A, Sander D, Scherbaum N, Schecke H. Substanzkonsum im sexuellen Kontext (\u201cChemsex\u201d) bei M\u00e4nnern, die Sex mit M\u00e4nnern haben\u2013Ergebnisse des \u201cGerman-Chemsex-Survey.\u201d Suchttherapie. 2024;25:83\u201391.","journal-title":"Suchttherapie"},{"key":"1428_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12141411","author":"P Del Pozo-Herce","year":"2024","unstructured":"Del Pozo-Herce P, Mart\u00ednez-Sabater A, Sanchez-Palomares P, Garcia-Boaventura PC, Chover-Sierra E, Mart\u00ednez-Pascual R, et al. Effectiveness of harm reduction interventions in chemsex: a systematic review. Healthcare. 2024. https:\/\/doi.org\/10.3390\/healthcare12141411.","journal-title":"Healthcare"},{"key":"1428_CR45","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). Basisdaten Psychische Erkrankungen: Stand April 2024; 2024."},{"key":"1428_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cpr.2018.04.002","volume":"69","author":"KP Lindgren","year":"2019","unstructured":"Lindgren KP, Hendershot CS, Ramirez JJ, Bernat E, Rangel-Gomez M, Peterson KP, et al. A dual process perspective on advances in cognitive science and alcohol use disorder. Clin Psychol Rev. 2019;69:83\u201396. https:\/\/doi.org\/10.1016\/j.cpr.2018.04.002.","journal-title":"Clin Psychol Rev"},{"key":"1428_CR47","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760\u201373. https:\/\/doi.org\/10.1016\/S2215-0366(16)00104-8.","journal-title":"Lancet Psychiatry"},{"key":"1428_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/11782218221118462","volume":"16","author":"A Farhoudian","year":"2022","unstructured":"Farhoudian A, Razaghi E, Hooshyari Z, Noroozi A, Pilevari A, Mokri A, et al. Barriers and facilitators to substance use disorder treatment: an overview of systematic reviews. Subst Abuse. 2022;16:11782218221118462. https:\/\/doi.org\/10.1177\/11782218221118462.","journal-title":"Subst Abuse"},{"key":"1428_CR49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/15563650.2017.1370097","volume":"56","author":"O Beck","year":"2018","unstructured":"Beck O, B\u00e4ckberg M, Signell P, Helander A. Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats. Clin Toxicol (Phila). 2018;56:256\u201363. https:\/\/doi.org\/10.1080\/15563650.2017.1370097.","journal-title":"Clin Toxicol (Phila)"},{"key":"1428_CR50","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m07822","volume":"74","author":"JA Niemi-Pyntt\u00e4ri","year":"2013","unstructured":"Niemi-Pyntt\u00e4ri JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74:20155.","journal-title":"J Clin Psychiatry"},{"key":"1428_CR51","doi-asserted-by":"publisher","unstructured":"Kalamara E, \u0160ka\u0159upov\u00e1 K. Monitoring drug use in the digital age: studies in web surveys: Quantitative and qualitative assessments of data quality within the European Web Survey on Drugs. EMCDDA Insights. https:\/\/doi.org\/10.2810\/802676.","DOI":"10.2810\/802676"},{"key":"1428_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00009","volume":"14","author":"A Zwartsen","year":"2020","unstructured":"Zwartsen A, Olijhoek ME, Westerink RHS, Hondebrink L. Hazard characterization of synthetic cathinones using viability, monoamine reuptake, and neuronal activity assays. Front Neurosci. 2020;14:9. https:\/\/doi.org\/10.3389\/fnins.2020.00009.","journal-title":"Front Neurosci"},{"key":"1428_CR53","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.neuro.2019.08.009","volume":"75","author":"J Soares","year":"2019","unstructured":"Soares J, Costa VM, Gaspar H, Santos S, Lourdes Bastos M, Carvalho F, et al. Structure-cytotoxicity relationship profile of 13 synthetic cathinones in differentiated human SH-SY5Y neuronal cells. Neurotoxicology. 2019;75:158\u201373. https:\/\/doi.org\/10.1016\/j.neuro.2019.08.009.","journal-title":"Neurotoxicology"},{"key":"1428_CR54","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1037\/a0034173","volume":"21","author":"BD Kiluk","year":"2013","unstructured":"Kiluk BD, Babuscio TA, Nich C, Carroll KM. Smokers versus snorters: do treatment outcomes differ according to route of cocaine administration? Exp Clin Psychopharmacol. 2013;21:490\u20138. https:\/\/doi.org\/10.1037\/a0034173.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1428_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12016-013-8376-9","volume":"46","author":"W Tseng","year":"2014","unstructured":"Tseng W, Sutter ME, Albertson TE. Review of literature. Clin Rev Allergy Immunol. 2014;46:82\u2013100. https:\/\/doi.org\/10.1007\/s12016-013-8376-9.","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01428-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:54:51Z","timestamp":1772690091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01428-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01428-8","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"23 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was pre-registered in the German Clinical Trials Register on 02\/2025 (drks.de\/search\/en\/trial\/DRKS00035946).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"Generative AI and AI-assisted technologies (e.g., ChatGPT) were used solely to improve the readability and language of the manuscript. No AI tools were employed to generate content, develop ideas, perform analysis, or contribute to the interpretation of findings. The authors take full responsibility for the content.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}